

## NCCN Cervical Cancer V.1.2011 — Follow-up — September 10, 2010

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<a href="#">CERV-A</a> Internal request: Remove epirubicin from the list of second-line therapy agents for recurrent or metastatic cervical cancer.	Based upon the lack of data to support its use and panel consensus, epirubicin was removed as a second-line therapy for recurrent or metastatic cervical cancer		11	2	3
<a href="#">CERV-A</a> Internal request: Remove liposomal doxorubicin from the list of second-line therapy agents for recurrent or metastatic cervical cancer.	Based upon the poor response rate and lack of data, the panel consensus was to remove liposomal doxorubicin as a second-line therapy for recurrent or metastatic cervical cancer.	Rose PG, Blessing JA, Lele, Abulafai O. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. <i>Gynecol Oncol</i> 2006;102(2):210-213.	10	3	3
<a href="#">CERV-A</a> Internal request: Remove pemetrexed from the list of second-line therapy agents for recurrent or metastatic cervical cancer.	Based upon the moderate activity of pemetrexed in advanced or recurrent cervical cancer and panel disagreement, pemetrexed changed from a category 2B to a category 3 recommendation for second-line therapy for recurrent or metastatic cervical cancer.	Miller DS, Blessing JA, Bodurka DC, et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. <i>Gynecol Oncol</i> . 2008; 110(1):65-70.	8	4	4
<a href="#">CERV-A</a> Internal request: Remove vinorelbine from the list of second-line therapy agents for recurrent or metastatic cervical cancer.	Based upon the moderate activity of vinorelbine in squamous cell carcinoma of the cervix, minimal activity in nonsquamous cancer of the cervix, and panel disagreement, vinorelbine changed from a category 2B to a category 3 recommendation for second-line therapy for recurrent or metastatic cervical cancer.	<ol style="list-style-type: none"> <li>Muggia FM, Blessing JA, Method M, et al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. <i>Gynecol Oncol</i> 2004; 92(2):639-643.</li> <li>Muggia FM, Blessing JA, Waggoner S, et al. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. <i>Gynecol Oncol</i> 2005;96(1):108-111.</li> </ol>	8	5	3